SCHEMBL10133967

SCHEMBL10133967

Cc1ccc(Cl)n2ccnc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SSTR4 P31391 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.34
FLT1 P17948 1/20 0.34
CDK8 P49336 1/20 0.34
CDK9 P50750 1/20 0.34
LIMK1 P53667 1/20 0.34
ROCK1 Q13464 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
CCNE1 P24864 3/20 0.33
CDK2 P24941 3/20 0.33
CCNE2 O96020 1/20 0.33
IKBKB O14920 1/20 0.33
ADORA2A P29274 2/20 0.33
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
GRIA1 P42261 1/20 0.33
GRIA2 P42262 1/20 0.33
GRIA3 P42263 1/20 0.33
GRIA4 P48058 1/20 0.33
GRIN1 Q05586 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12653259 0.79 SSTR4 (0.41) SSTR4L3MBTL1FLT1CDK8CDK9
SCHEMBL22490646 0.79 CCNE1 (0.38) CCNE1CDK2CCNE2ADORA2AGRIN2D
SCHEMBL2674372 0.76 L3MBTL1 (0.42) SSTR4L3MBTL1FLT1CDK8CDK9
SCHEMBL18643298 0.76 SSTR4 (0.36) SSTR4L3MBTL1FLT1CDK8CDK9
SCHEMBL30326244 0.76 CCNE1 (0.33) L3MBTL1CCNE1CDK2CCNE2ADORA2A
SCHEMBL1685106 0.76 CCNE1 (0.36) CCNE1CDK2CCNE2GRIN2DGRIN3B
SCHEMBL31682490 0.73 CCNE2 (0.32) CCNE1CDK2CCNE2GRIN2DGRIN3B
SCHEMBL22814529 0.72 L3MBTL1 (0.34) L3MBTL1FLT1CDK8CDK9LIMK1
SCHEMBL8829291 0.72 PTPN1 (0.34) L3MBTL1FLT1CDK8CDK9LIMK1
SCHEMBL23811383 0.72 L3MBTL1 (0.42) L3MBTL1IKBKBADORA2AGRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-7951818-B2 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-05-31 US disclosed
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES COL2A1, MMP1, COL1A1 SSTR4 4396/4885L3MBTL1 4815/4885FLT1 2365/4885
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases COL2A1, MMP1, COL1A1 SSTR4 4396/4885L3MBTL1 4815/4885FLT1 2365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.